Lysosomal Acid Liapse (LAL) Deficiency Treatment Market

Publisher: AnalystView Market Insights
Publication Date: June, 2020
Healthcare / Medical Equipment
Pages: 158
Delivery Format: PDF

By Treatment (ERT, Stem Cell Therapy, Lipid Modifying Agents, Supportive Care, Surgery), By Indication (CESD, Wolman Disease), and By Geography (NA, EU, APAC, LATAM and MEA) Ð Analysis, Share, Trends, Size, & Forecast From 2020 Ð 2026

Report Features
Table of Contents
Pricing
Methodology
Request Sample
Compare Offers
Make an Offer

REPORT HIGHLIGHT
Lysosomal Acid Liapse (LAL) Deficiency Treatment market was valued at USD 390.5 million by 2019, growing with 9.9% CAGR during the forecast period, 2020-2026
Market Dynamics
The growing adoption of enzyme replacement therapy for treatment is one of the major factors driving the growth of global lysosomal acid lipase deficiency (LAL-D) treatment market. In addition, large patient pool and high prevalence of lysosomal acid lipase deficiency are other factors boosting the market growth. LAL-D is a rare type of lysosomal storage disorder, wherein patients are not able to triglycerides and cholesteryl esters due to a mutation in the lysosomal acid lipase gene. Thus, there is an accumulation of lipids in the walls of blood vessels, spleen, and liver. LAL-D is a progressive disease with early mortality due to liver failure, medical complications, and multi-systemic clinical manifestations. Moreover, governments of both developed and developing countries are taking the initiative to make people aware of the LAL-D treatment. Also, pharmaceutical companies are investing more in research and development to provide better treatment for patients. This is anticipated to create lucrative opportunities in the global industry during the forecast period. However, high costs associated with treatment and lack of awareness amongst individuals regarding LAL-D treatment are predicted to hamper the market growth in the coming future.
The current management of LAL-D is majorly focused on nutritional support and nutritional care. The supportive care segment dominated the global market in 2018 mainly because it includes high triglycerides and cholesterol through lipid-lowering statins, low-fat diet, apolipoprotein B production, and management of plasma lipid levels. Along with supportive care, the enzyme replacement therapy (ERT) segment is estimated to grow at the fastest CAGR during the forecast period. This rapid growth is majorly due to high efficiency and long-term disease control post-treatment.
Treatment Takeaway
The cholesteryl ester storage disease (CESD) segment is anticipated to witness the fastest growth during the forecast period. This rapid growth is majorly due to the increasing uptake of ERT and high disease prevalence. In addition, the CSED has a higher prevalence rate than the Wolman disease. On the other hand, the Wolman disease is considered to be of the more severe form, which has an early onset. It occurs due to non-existence of lysosomal acid lipase enzyme activity. There are no clinical signs shown by infants at the time of birth, but after a few months suffer from vomiting, diarrhoea, jaundice, and develop enlarged spleens and livers.
Regional Takeaway
The North America region dominated the global LAL-D treatment market in 2018 followed by Europe. North America is poised to lead the market by the end of 2030 owing to the presence of a large patient pool and high disease prevalence. Europe region is estimated to be the second-largest market owing to the growing occurrence of disease and rising uptake of Kanuma.
Key Vendors Takeaway
Limited therapeutic intervention for LAL-D and increasing eligible patient population is expected to offer a strong commercial opportunity to major industry players to invest in the development of novel treatments in the global market.
Key players of the market include:
¥ Alexion Pharmaceutical Inc.
¥ Merck & Co., Inc.
¥ AstraZeneca plc.
¥ Teva Pharmaceutical Industries Ltd.
¥ Pfizer, Inc.
The market size and forecast for each segment and sub-segments has been considered as below:
¥ Historical Year Ð 2015 to 2018
¥ Base Year Ð 2019
¥ Estimated Year Ð 2020
¥ Projected Year Ð 2026
TARGET AUDIENCE
? Traders, Distributors, and Suppliers
? Manufacturers
? Government and Regional Agencies
? Research Organizations
? Consultants
? Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY TREATMENT
? Lipid Modifying Agents (Statins)
? Enzyme Replacement Therapy (ERT)
? Stem Cell Therapy
? Supportive Care
? Surgery
GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY INDICATION
? Cholesteryl Ester Storage Disease (CESD)
? Wolman Disease (WD)
? Others
GLOBAL LYSOSOMAL ACID LIAPSE (LAL) DEFICIENCY TREATMENT MARKET, BY REGION
? North America
o The U.S.
o Canada
? Europe
o Germany
o France
o Italy
o Spain
o United Kingdom
o Rest of Europe
? Asia Pacific
o India
o China
o South Korea
o Japan
o Singapore
o Rest of APAC
? Latin America
o Brazil
o Mexico
o Argentina
o Rest of LATAM
? Middle East and Africa
o Saudi Arabia
o United Arab Emirates
o Rest of MEA

Offer Amount (Per user license)	Retail price (Per user license)
$ .00	$3,250

Lysosomal Acid Liapse (LAL) Deficiency Treatment Market

Are you looking for a Consultant?

Customers Who Viewed This Item Also Viewed